不同剂量的rhG-CSF对恶性血液病患者化疗后白细胞减少持续时间及白细胞水平的影响

发布时间：2019-02-13 00:17

【摘要】：目的:比较不同剂量rhG-CSF对恶性血液病患者化疗后白细胞减少持续时间和外周血象的影响。方法:选取2011年12月-2016年6月期间我院收治的90例的恶性血液病患者作为观察组;选取2004年1月-2007年1月期间的30例患者作为对照组,所有患者均接受标准化疗方案。将观察组患者随机分为A(rhG-CSF 200μg/m~2)、B(rhG-CSF 300μg/m~2)和C(rhG-CSF 400μg/m~2)3组。比较观察组和对照组化疗前后白细胞最低值(WBC_(min))及其持续时间,最高值(WBC_(max))及其出现时间;比较患者治疗期间的感染发生率、rhG-CSF的总用量及不良反应发生率。结果:对照组外周血WBC_(min)为(1.30±0.11)×10~9/L,持续时间(3.2±0.7)d,WBC_(max)为(5.14±0.41)×10~9/L,出现时间(26.1±1.8)d;A组分别为(3.14±0.23)×10~9/L,(2.7±1.0)d,(10.08±0.69)×10~9/L及(14.9±1.8)d;B组分别为(3.11±0.32)×10~9/L,(0.9±0.5)d,(10.17±0.75)×10~9L及(10.7±1.5)d;C组分别为(3.15±0.30)×10~9/L,(0.5±0.3)d,(11.95±0.86)×10~9/L及(10.6±1.5)d。与对照组相比,A、B、C组WBC_(min)持续时间缩短,WBC数最小值及最大值均明显升高,WBC最大值出现提前,其差异均有统计学意义(P0.05)。对照组感染率33.33%,显著高于C组的3.33%(P0.05);A、B、C组间感染率、不良反应发生率及rhGCSF的差异无统计学意义(P0.05)。结论:与低剂量的rhG-CSF相比,中、高剂量的rhG-CSF能够明显缩短恶性血液病患者化疗后白细胞减少持续时间。
[Abstract]:Aim: to compare the effects of different doses of rhG-CSF on leukopenia duration and peripheral blood count in patients with malignant hematopathy after chemotherapy. Methods: from December 2011 to June 2016, 90 patients with malignant hematologic diseases were selected as observation group, 30 patients from January 2004 to January 2007 as control group, all patients received standard chemotherapy regimen. The patients in the observation group were randomly divided into three groups: group A (rhG-CSF 200 渭 g/m~2), B (rhG-CSF 300 渭 g/m~2) and group C (rhG-CSF 400 渭 g/m~2). The leucocyte minimum (WBC_ (min) and its duration, WBC_ (max) and its appearance time) before and after chemotherapy were compared between the observation group and the control group. The incidence of infection, the total dosage of rhG-CSF and the incidence of adverse reactions were compared. Results: in the control group, the WBC_ (min) of peripheral blood was (1.30 卤0.11) 脳 10 ~ (9) / L, the duration was (3.2 卤0.7) DBC _ (max) (5.14 卤0.41) 脳 10 ~ (9) / L, and the time of appearance was (26.1 卤1.8) days. Group A was (3.14 卤0.23) 脳 10 ~ (9) / L, (2.7 卤1.0) d, () 10.08 卤0.69 脳 10 ~ (9) / L and (14.9 卤1.8) d; Group B was (3.11 卤0.32) 脳 10 ~ (9) / L, (0.9 卤0.5) d, (10.17 卤0.75 脳 10 ~ (9) L and (10.7 卤1.5) d; Group C was (3.15 卤0.30) 脳 10 ~ (9) / L, (0.5 卤0.3) d, (11.95 卤0.86) 脳 10 ~ (9) / L and (10.6 卤1.5) days respectively. Compared with the control group, the duration of WBC_ (min) was shortened, the minimum value and maximum value of WBC were significantly increased, and the maximum value of WBC appeared earlier in group A, and the difference was statistically significant (P0.05). The infection rate in the control group was 33.33%, significantly higher than that in group C (3.33%, P0.05), while there was no significant difference in the infection rate, adverse reaction rate and rhGCSF between the two groups (P0.05). Conclusion: compared with low dose rhG-CSF, high dose rhG-CSF can significantly shorten the duration of leukopenia after chemotherapy in patients with malignant hematologic diseases.
【作者单位】：商丘市第一人民医院血液内科;
【分类号】：R733

【相似文献】